- Global Pharma News & Resources

3D Printed Drugs Market Projected to Improvement of Growth in The Coming Years

Dysphagia is more common in older populations and children and can cause dysphagia. 3D-printed drugs are gaining popularity as the FDA has passed the priority review voucher system. In addition, the growing elderly population and technological advances in 3D pointing procedures are expected to contribute to market growth.

3D Printed Drugs Market is estimated to be $278 million in 2020, and would reach $522 million by 2030, growing at a CAGR of 6.5% from 2020 to 2030. U.S. market holds the highest market share in 2020.

3D printing drugs are drugs created by 3D printing technology used to treat patients suffering from dysphagia. 3D printing drugs have a porous structure that can collapse rapidly in the oral cavity. SPRITAM levetiracetam from Aprecia Pharmaceuticals Companies is the first 3D printing drug approved by the US Food and Drug Administration (FDA) in August 2015.

Download PDF Report Sample with statistical info @

The key players profiled in this report include

Aprecia Pharmaceuticals

GlaxoSmithKline Plc.

Hewlett Packard Caribe


3D Printer Drug Machine

FabRx Ltd.

The organizations engaged in the research of 3D printed drugs included in this report are UCL School of Pharmacy, University of Glasgow, University College London, The University of Nottingham, and National University of Singapore.

Constant technological developments in 3D printing technique, rise in incidence of epilepsy cases, and increase in awareness about the 3D printing technology in the developing countries drive the growth of the market. However, lack of government regulations related to these drugs and adverse effects of 3D printed drugs are expected to limit the market growth.

The global 3D printed drugs market is analyzed based on forecast scenario such as low growth scenario, moderate growth scenario, and rapid growth scenario.

According to low growth scenario, the U.S. is anticipated to account for the highest market share in 2020, and rest of North America market is expected to grow at the highest rate, registering the CAGR of 5.1% by 2030.

Europe is estimated to account for four-sevenths share in 2020, and is expected to dominate the market throughout the forecast period, due to presence of well-established healthcare systems and increase in prevalence of dysphagia. In addition, increase in adoption of 3D printed drugs is anticipated to provide new growth opportunities for the key players in the European market. However, Asia-Pacific is projected to grow at the highest growth rate during the analysis period, owing to increase in healthcare expenditure, rise in awareness related to 3D printing technique, presence of large patient pool, and developments in healthcare infrastructure.

Key Findings of 3D Printed Drugs Market:

In North America, the U.S. is anticipated to dominate the market in 2020, whereas rest of North America is projected to grow at the highest CAGR during the forecast period.

Germany was the major shareholder in the European 3D printed drugs market in 2016.

Asia-Pacific is expected to register the highest growth rate in future.

Australia is expected to grow at the highest CAGR in the Asia-Pacific 3D printed drugs market.

Make an Enquiry for Promocode Of Discounted Price: @

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at

Editor Details

Last Updated: 11-Feb-2020